Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

251 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.
Stern HM, Gardner H, Burzykowski T, Elatre W, O'Brien C, Lackner MR, Pestano GA, Santiago A, Villalobos I, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Nuciforo P, Bee V, Mackey J, Slamon DJ, Press MF. Stern HM, et al. Clin Cancer Res. 2015 May 1;21(9):2065-74. doi: 10.1158/1078-0432.CCR-14-2993. Epub 2015 Feb 3. Clin Cancer Res. 2015. PMID: 25649019 Free PMC article. Clinical Trial.
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).
Perez EA, Press MF, Dueck AC, Jenkins RB, Kim C, Chen B, Villalobos I, Paik S, Buyse M, Wiktor AE, Meyer R, Finnigan M, Zujewski J, Shing M, Stern HM, Lingle WL, Reinholz MM, Slamon DJ. Perez EA, et al. Breast Cancer Res Treat. 2013 Feb;138(1):99-108. doi: 10.1007/s10549-013-2444-y. Epub 2013 Feb 19. Breast Cancer Res Treat. 2013. PMID: 23420271 Free PMC article.
Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.
Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, Leiberman G, Slamon DJ. Mass RD, et al. Clin Breast Cancer. 2005 Aug;6(3):240-6. doi: 10.3816/CBC.2005.n.026. Clin Breast Cancer. 2005. PMID: 16137435
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Bee V, Taupin H, Flom KJ, Tabah-Fisch I, Pauletti G, Lindsay MA, Riva A, Slamon DJ. Press MF, et al. J Clin Oncol. 2011 Mar 1;29(7):859-67. doi: 10.1200/JCO.2009.27.5644. Epub 2010 Dec 28. J Clin Oncol. 2011. PMID: 21189395 Free PMC article. Clinical Trial.
A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01).
Hurvitz SA, Allen HJ, Moroose RL, Chan D, Hagenstad C, Applebaum SH, Patel G, Hu EH, Ryba N, Lin LS, Wang H, Glaspy J, Slamon DJ, Kabbinavar F. Hurvitz SA, et al. Clin Breast Cancer. 2010 Aug 1;10(4):307-12. doi: 10.3816/CBC.2010.n.040. Clin Breast Cancer. 2010. PMID: 20705564 Clinical Trial.
Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ, Finn RS. Wainberg ZA, et al. Clin Cancer Res. 2010 Mar 1;16(5):1509-19. doi: 10.1158/1078-0432.CCR-09-1112. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179222
Advances in adjuvant therapy for breast cancer.
Slamon DJ, Romond EH, Perez EA; CME Consultants, Inc. Slamon DJ, et al. Clin Adv Hematol Oncol. 2006 Mar;4(3 Suppl 7):suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10. Clin Adv Hematol Oncol. 2006. PMID: 16736568
251 results
Jump to page
Feedback